Learn more about Hexima’s technology.
Hexima is conducting a phase I/IIa clinical trial of its lead antifungal molecule, HXP124, as a treatment for fungal nail infections.
Hexima Limited is pleased to announce the appointment of Mr Michael Aldridge as Chief Business Officer and a member of the Board of Directors, effective 21 May 2019. Mr Aldridge will be based in San Francisco, focussing on business development and establishing...
Hexima Limited today announced additional positive results from the second part of its ongoing phase 1/2a clinical trial for HXP124 as a novel topical treatment for fungal nail infections (onychomycosis). “These latest results confirm our interim data that HXP124...
View Hexima's Interim Financial Report (pdf) for the six months ended 31 December 2018.
Hexima Limited has announced the appointment of Mr Scott Robertson to its Board of Directors, effective 21 November 2018. Speaking at Hexima’s recent AGM, Chairman Professor Jonathan West said “I am pleased to announce today that we will be adding Mr Scott Robertson...
Presentations and Results from the 2018 Hexima Limited Annual General Meeting held 20 November 2018. AGM 2018 Chairman’s Address AGM 2018 CEO & CSO Presentation AGM 2018 Meeting Results